Printer Friendly

OSTEOTECH'S POLYACTIVE POLYMER PRESENTED AT INTERNATIONAL BIOMATERIALS MEETING

 SHREWSBURY, N.J., Feb. 17 /PRNewswire/ -- Osteotech's Polyactive(TM) polymer was the subject of presentations highlighting the technology's bone bonding and tissue augmentation capabilities at a major international conference on Bone Bonding Biomaterials held at the University of Leiden, the Netherlands on Jan. 30. The conference was sponsored by the University's Biomaterials Research Group (BRG) and was attended by research representatives from 18 countries interested in the future of biomaterials in musculoskeletal applications.
 Clemens van Blitterswijk, Ph.D., chief researcher of the Polyactive material for the BRG and scientific director of Osteoech's subsidiary, HC Implants, said that, "The Polyactive polymer system represents a new generation of bioactive medical implants." The resorbable polymer, developed jointly by HC Implants, and the Biomaterials Research Group in Leiden, features unique properties rendering it suitable for use in a wide range of medical applications.
 Extensive laboratory and animal studies conducted by the BRG have demonstrated that Polyactive, like bone tissue, absorbs water, calcifies and bonds directly to bone. Coupled with a high degree of biocompatibility and absorbability, these properties allow Polyactive to both complement bone replacement techniques and facilitate bone regrowth. Also at the international conference, Jan Grote, M.D., professor and chairman of the Ear Nose and Throat Department at the University of Leiden presented his positive human results in patients on the use of Polyactive as a replacement for the tympanic membrane in middle ear surgery.
 Osteotech, who acquired HC/CAM Implants, a worldwide leader in bioceramic and biomaterial technology, in the second quarter of 1992, is developing products with bone bonding capability for orthopaedic applications, as well as anti-adhesion sheets for use in spinal and general surgical procedures. Dental membranes and wound coverings are also under development. "We believe Osteotech will build a leadership position in the field of orthopaedic biomaterials with the Polyactive technology as the cornerstone. Coupled with the company's biologic technology, these biomaterials position Osteotech for future growth in emerging market opportunities in musculoskeletal surgery," stated Patrick McBrayer, the company's president and CEO. "Polyactive also represents opportunities for corporate partnerships which address other surgical applications," he further stated.
 Osteotech, Inc. headquartered in Shrewsbury, N.J., is a leading processor of human bone and bone connective tissue for transplantation and an innovator in the development of biologic and biomaterial products for musculoskeletal surgery.
 -0- 2/17/93
 /CONTACT: Michael J. Jeffries of Osteotech, 908-542-2800/
 (OSTE)


CO: Osteotech Inc. ST: New Jersey IN: MTC SU:

AH-PS -- NY017 -- 7201 02/17/93 10:05 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 17, 1993
Words:413
Previous Article:SUNBEAM-OSTER DECLARES QUARTERLY CASH DIVIDEND ON ITS COMMON STOCK
Next Article:AMERICA'S FASTEST GROWING PRODUCT COMPANIES EXPECT TO ACHIEVE COMEBACK IN 1993, WHILE SERVICE FIRM GROWTH FLATTENS: COOPERS & LYBRAND SURVEY
Topics:


Related Articles
CORRECTION TO OSTEOTECH ANNOUNCES ACQUISITION OF DUTCH/U.S. ORTHOPEDIC/DENTAL TECHNOLOGY COMPANY
OSTEOTECH RECEIVES PATENT ON ARTIFICIAL SKIN
OSTEOTECH SIGNS EXCLUSIVE AGREEMENT FOR DEVICES AND INSTRUMENTS FOR TREATMENT OF BONE TRAUMA
OSTEOTECH ANNOUNCES 35 PERCENT REVENUE INCREASE FOR SIX-MONTH PERIOD; EARNINGS ALSO INCREASE SIGNIFICANTLY
OSTEOTECH AWARDED GRANT BY DUTCH GOVERNMENT FOR RESEARCH ON POLYACTIVE
OSTEOTECH'S GROWTH CONTINUES; ACHIEVES 27% INCREASE IN REVENUES IN FIRST NINE MONTHS OF 1994
OSTEOTECH, INC. ANNOUNCES AMERICAN RED CROSS TO DISTRIBUTE GRAFTON DEMINERALIZED BONE MATRIX AND INTENDS TO RENEW LONG-TERM PROCESSING AGREEMENT
OSTEOTECH REPORTS RECORD THIRD QUARTER REVENUES AND EARNINGS
OSTEOTECH APPOINTS CHIEF SCIENTIFIC OFFICER
OSTEOTECH ANNOUNCES RECORD 1995 REVENUES AND EARNINGS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters